@Article{,
AUTHOR = {Yuding Wang, Shawn Dason, Bobby Shayegan},
TITLE = {How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {23},
YEAR = {2016},
NUMBER = {4},
PAGES = {8388--8394},
URL = {http://www.techscience.com/CJU/v23n4/61149},
ISSN = {1488-5581},
ABSTRACT = {Abiraterone acetate (AA) is a selective irreversible inhibitor 
of CYP 17, a key enzyme in androgen biosynthesis. The 
efficacy and safety of AA in improving survival and 
quality of life in metastatic castration resistant prostate 
cancer (mCRPC) has been demonstrated in two landmark 
clinical trials (COU-AA-301 and COU-AA-302). This 
article will review the rationale, pharmacology, clinical 
indications and contraindications, administration, and 
adverse effects of AA administration in mCRPC.},
DOI = {}
}